BioPharma & Healthcare Related News

eGenesis Announces $38 Million Series A Financing, Led by Biomatics Capital and ARCH Venture Partners, to Solve Shortage of Organs for Donation

Cambridge, Mass., March 16, 2017 — eGenesis, a biotechnology company focused on utilizing genome editing technology to make xenotransplantation a routine and lifesaving medical procedure, today announced that it raised a $38 million Series A financing co-led by Biomatics Capital [...]

By | March 20th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Editas Medicine, Inc. Announces Pricing of $90 Million Offering of Common Stock

CAMBRIDGE, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 4,000,000 shares of its common stock at a price to the public of $22.50 [...]

By | March 20th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases

DUBLIN, Ireland and CAMBRIDGE, Mass., March 14, 2017 (GLOBE NEWSWIRE) -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and [...]

By | March 14th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Intrexon Creates Precigen, Inc. and Accelerates Strategic Review of Structural Options Related to Health Assets

GERMANTOWN, Md., March 10, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the formation of Precigen, Inc., a wholly-owned [...]

By | March 14th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Intellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid Nanoparticle Delivery Technology

CAMBRIDGE, Mass., March 08, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapies, today reported updated data showing increased levels of genome editing efficiency in vivo and durability [...]

By | March 9th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Kite Pharma’s Engineered T-Cell Therapies for Cancers Delivers Astonishing Results

Kite Pharma’s gene therapy trial has just delivered astonishing results: 41% of patients in response and 36% in complete response at month 6 after a single round of treatment. The news shook the bio and med industry last week, skyrocketing [...]

By | March 7th, 2017|BioPharma & Healthcare, News, Therapeutics|